Mounjaro for its superior ability to control blood sugar in people with diabetes, and semaglutide for its stunning weight-loss results
Uncropped full-length images of immunoblots are shown in Supplementary Fig
Brainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat
In a 26-week phase 2 study involving patients with obesity and T2DM, treatment with tirzepatide dose-dependently decreased the circulating levels of specific biomarkers of inflammation and endothelial dysfunction previously associated with cardiovascular events, suggesting a net improvement in the cardiovascular risk profile of these patients.37 In this post hoc analysis, inflammation, endothelial dysfunction, and cellular stress biomarkers were measured at baseline and 4, 12, and 26 weeks to evaluate the additional effects of tirzepatide on cardiovascular risk factors.37 After 26 weeks, tirzepatide treatment at doses of 10 and 15 mg decreased the levels of YKL-40 (also known as chitinase-3 like-protein-1), intercellular adhesion molecule 1 (ICAM-1), leptin, and growth differentiation factor 15 compared with baseline
Additionally, pathogenic soluble tau proteins impair endothelium-dependent CBF responses, leading to microvascular deficits
